Navigation Links
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Date:10/8/2008


-- Exploratory study shows clinical improvement in patients with pulmonary

arterial hypertension (PAH)

-- Current treatment options have limited benefit for this debilitating,

rapidly progressive and incurable blood vessel disease

-- Imatinib mesylate, available as Gleevec(R) for treatment of certain

cancers, known to inhibit protein associated with PAH

-- Novartis to further explore potential of imatinib mesylate in PAH in

2009

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.

Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in cardiac output, key hemodynamic measures used to monitor the progression of the disease. Improvements in the six-minute walk test, the primary endpoint of the study, approached, but did not reach, statistical significance.

These initial data were presented today at the European Respiratory Society (ERS) congress in Berlin, Germany, and further details on the study are expected to be published later this year. Imatinib mesylate is available for oncology indications as Gleevec(R) in the US, Canada and Israel and as Glivec(R) (imatinib), in countries outside of the US, Canada and Israel.

"The outcomes of this trial are clinically important given the rapid progression of PAH and the poor prognosis for these patients," said Professor Ardeschir Ghofrani, MD, Head of Pulmonary Hypertension Division, University Hospital Giessen und Marburg, Germany. "Our observations suggest that imatinib mesylate holds promise in treating PAH."

PAH is a de
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
5. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
6. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
7. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
8. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
9. Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
10. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Disease Control and Neurotoxicity Data To Be Presented ... Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for ... Team to Host Analyst and Investor Briefing to ... SAN FRANCISCO, Calif., May 28 Poniard Pharmaceuticals, ...
... and Melanoma Studies - Conference Call to be Hosted ... Conn., May 28 CuraGen Corporation (Nasdaq: ... data presentations from its ongoing clinical trials of CR011-vcMMAE, ... advanced breast cancer and melanoma at the 2009 Annual ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:2/28/2015)... February 28, 2015 The MCA Youth ... Malaysia into one platform and gears towards the goal ... A series of group talks in smaller groups will ... Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and ... awareness of Malaysian youths. , Young adults ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... 2015 March—also known as National ... remind ourselves and others that suspected head injuries, ... Specialists (ANS). , Concussions are a form of ... of TBIs. There are 1.6-3.8 million sports-related concussions ... but it is a brain injury. Many athletes ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... R.I. [Brown University] Despite evidence that feeding tubes ... for elderly patients with advanced dementia, their frequency of ... of family members finds that discussions surrounding the decision ... Advanced dementia is a terminal illness that often affects ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... of disease progression and response to chemotherapy in breast ... patients, but do not always agree in their predictions ... In recent years, several genomic tests have ... Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, ...
... In a rare and medically remarkable operation, a multi-disciplinary team ... Arthur G. James Cancer Hospital and Richard J. Solove ... and pelvis of a cancer patient, and used the healthy, ... connection between his spine and remaining right pelvis to support ...
... May 4 (HealthDay News) -- U.S. health officials issued ... of liquid over-the-counter drug products that are measured and ... droppers. The U.S. Food and Drug Administration developed ... of overdoses when using liquid over-the-counter (OTC) pain relievers, ...
... , WEDNESDAY, May 4 (HealthDay News) -- A ... group of congenital heart defects that cause a major proportion ... unclear how these cardiac defects -- all malformations of the ... suggests a genetic component may play a role. "It ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
... Infrapatellar Band uses an aircell ... patellar tendon helping to relieve ... patella tendonitis. Focusing the pressure ... tubercle with less constriction of ...
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: